Andreas Müller

Partner, Attorney-at-law, LL.M.

andreas.mueller@nkf.ch
D +41 58 800 84 20

Languages

German, English, French

Expertise

Andreas Müller is an M&A, corporate, capital markets and executive compensation specialist. Andreas acts as advisor on buy- and sell-side public and private M&A transactions and to issuers and investors in equity and hybrid financing transactions. In addition, he advises boards, board committees and companies on complex corporate governance, securities law and executive compensation matters and activist defense. He also acts as advisor in corporate restructurings and general corporate and commercial matters.

He is admitted to practice in Switzerland and New York and recognized as an authorized issuer's representative at the SIX Swiss Exchange. He has published numerous articles on corporate, securities and commercial law, corporate governance and executive compensation topics in Swiss and international commentaries and journals. He is an editor of one of Switzerland's leading legal journals on corporate and capital markets law (Schweizerische Zeitschrift für Gesellschafts- und Kapitalmarktrecht, GesKR) and the editor of the leading commentary on Swiss executive compensation rules.

Corporate / M&A | Capital Markets | Employment

Career

2026	Partner, Niederer Kraft Frey
2020	Partner at Homburger AG
2016	Associate, Freshfields Bruckhaus Deringer LLP, London
2013	Associate at Homburger AG
2009	Law clerk, District Court of Arlesheim
2008	Junior Associate at a major Swiss law firm

Education

2013	PhD in Law (Dr. iur.), University of Basel

2013	Admitted to the New York Bar
2012	Harvard Law School (LL.M.)
2010	Admitted to the Swiss Bar (Attorney-at-law)
2008	University of Basel (lic. iur.)

Experience

Experience highlights (prior to joining NKF) include advising:

M&A

- DALI Discount on the secondary investment by ALDI SÜD Group (2026)
- 908 Devices on its acquisition of NIRLAB (2026)
- AECOM on its acquisition of Norwegian AI company Consigli (2026)
- HWP Group on the acquisition of Global Market Access Solutions (2026)
- Element Solutions on its USD 500 m acquisition of Micromax from Celanese (2026)
- Clariness AG on the sale to SubjectWell, Inc. (2026)
- Windward Bio on its up to USD 700 m licensing deal with Qyuns (2025) and its licensing deal with Kelun-Biotech and Harbour BioMed (2025)
- Biocorp on SK Capital's EUR 1.5 bn investment in Swixx BioPharma (2025)
- Marex Group plc on the acquisition of fixed-income market maker Valcourt SA (2025)
- ABB on the carve-out and USD 5.375 bn sale of its robotics division to SoftBank (2025) and on the separation of the Power Grids business and the completion of its USD 11 bn divestment to Hitachi (2020)
- Zurich Airport on its CHF 155 m purchase of the Radisson Blu Building at Zurich Airport (2025)
- UBS on the merger of Pillar 2-FZG and Pillar 3a pension foundations (2025)
- BIOTRONIK on sale of VI Business to Teleflex (2025)
- HR Group on its acquisition of H-Hotels (2025)
- Novo Nordisk / Novo Holdings on its USD 11 bn acquisition of Catalent (2025)
- Pollen Street Capital on its acquisition of Etops Group (2024)
- Lotus Bakeries on its strategic partnership with Mondelēz International (2024)
- Biocorp on its USD 220 m sale of Biopas to Swixx Biopharma (2024)
- Müller Martini on its acquisition of Hunkeler (2023)
- VectivBio with respect to the USD 1 bn public cash tender offer from Ironwood Pharmaceuticals (2023) and on its acquisition of Comet Therapeutics (2021)
- AEQUITA on its acquisition of Saint-Gobain's Swiss Glassolutions Business (2023)
- Solenis on the USD 4.6 bn acquisition of Diversey (2023) and its acquisition of Kolb's paper process chemicals business (2022)
- Credit Suisse on its merger with UBS (2023)

- Affective Advisory GmbH and the seller on joining forces with «Team Farner» (2023)
- Tiedemann Group on its business combination with Alvarium Investments and Cartesian Growth Corporation to form Nasdaq-listed AlTi (2023)
- AMF Medical and its shareholders on the CHF 200 bn sale of AMF Medical to Tandem Diabetes Care (2022)
- I.G. Capital on its acquisition of Celerion (2022)
- Avolta (formerly Dufry) on the USD 6.7 bn strategic combination with Autogrill (2022), its acquisition of all remaining equity interest in Hudson and the related equity financing (2020), its CHF 3.8 bn acquisition of World Duty Free (2015), its CHF 1.55 bn acquisition of The Nuance Group (2014), its USD 446 m acquisition of Hudson Group (2008) and its EUR 328 m acquisition of the remaining 49% of Hellenic Duty Free (2013)
- Ahlström Capital on the merger of Enics with GPV (2022)
- Azolver Holding on the sale of all its operative subsidiaries to Francotyp-Postalia (2022)
- Sonova on its acquisition of Sennheiser's Consumer Division (2022)
- Metall Zug on the quasi-merger of its Business Unit Wire Processing with Komax (2022)
- Nitto on the sale of its specialized adhesive films technology for side curtain airbags to ZF (2022)
- ASML on the sale of Berliner Glas Medical and SwissOptic (2021) and its acquisition of Berliner Glas (2020)
- Platinum Equity in its USD 5.25 bn acquisition of Solenis (2021)
- Grünenthal on its acquisition of Mestex (2021)
- ARYZTA AG on the USD 850 mn disposal of its North American business to Lindsay Goldberg (2021)
- TPG Growth in its acquisition of People 2.0 (2021)
- Silversmith Capital Partners and Appfire Technologies on its acquisition of beecom Products (2020)
- Tiedemann Advisors and Constantia Partners on their joint venture Tiedemann Constantia (2019)
- Sale of Therachon with its Achondroplasia program to Pfizer (up to USD 810 m) and the spin-off of Therachon's Apraglutide program (2019)
- Finatem IV on its acquisition of a majority stake in Mungo Befestigungstechnik (2018)
- Clariant on a MoU with SABIC regarding the combination of high performance materials businesses and on its entry into a governance agreement with SABIC regarding future governance principles of Clariant (2018), on the CHF 2.35 bn sale of activist shareholder White Tale's 24.99% stake to SABIC (2018) and on its planned USD 20 bn cross-border merger with Huntsman Corporation (2017)
- Sulzer on the CHF 500 m acquisition of 5 m Sulzer shares from Renova (2018)
- H. and Dr. G. Abivardi on the sale of swiss smile and their reinvestment to Jacobs Holding (2017)
- Fairfax Financial on its USD 4.9 bn acquisition of Allied World Assurance Company Holdings, AG (2016)
- Boehringer Ingelheim on the USD 22.7 bn swap of its consumer healthcare business for Sanofi's animal health business (2016)
- Generali on the CHF 1.25 bn sale of BSI to BTG Pactual (2015)
- Givaudan on its acquisition of Induchem (2015)
- Royal Bank of Scotland on the sale of Coutts International to Union Bancaire Privée (2015)
- Kaba on its CHF 4 bn cross-border merger with Dorma Group (2015)
- Holcim on its CHF 41 bn merger with Lafarge (2014 / 2015)

— Tyco International on its redomiciliation from Switzerland to Ireland (2014)

Investment and Equity-Based Financing Transactions

— Representing biotech, medtech and life science companies, including ADC Therapeutics, Alentis Therapeutics, AMF Medical, VectivBio, Windward Bio, as well as investors such as Baker Brothers, Novo Holdings and Hevolution Foundation

— Representing tech and AI companies, including Kandou AI and wefox, as well as investors such as General Catalyst and NVentures (NVIDIA)

— DALI DISCOUNT AG in connection with its financing rounds, including the Series D financing round by ALDI SÜD Group (2022-2026)

Capital Market Transactions

— Kühne + Nagel International on its long-term strategic collaboration with Amazon, including a call option structure (2026)

— Liberty Global and Sunrise on the spin-off and listing of Sunrise on the SIX and NASDAQ (2024)

— Galderma on its USD 12 bn IPO on SIX Swiss Exchange (2024)

— Luzerner Kantonalbank on its CHF 489 m rights offering (2023)

— Credit Suisse Group AG on its CHF 4 bn private placement and rights offering (2022)

— VectivBio on its IPO on Nasdaq (2021), its follow-on public offering and concurrent private placement (2022) and its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital (2022)

— Dufry on its CHF 700 m rights offering with commitments from Advent International and Alibaba Group and its strategic joint venture with Alibaba Group (2020) and its placement of 5.5 m shares and CHF 350 m convertible bonds (2020)

— ADC Therapeutics SA on its IPO on NYSE (2020)

— Dufry on the USD 1.6 bn IPO of its subsidiary Hudson on NYSE (2018)

Executive Compensation

— Advised almost all top 50 Swiss listed companies as well as numerous other listed companies on compliance with Swiss executive compensation ("Minder") rules

— Frequently advises on all legal aspects of hires and departures of top executives

— Regularly advises public and privately held companies on the design and implementation of their cash- and equity-based incentive plans

— Advisor to numerous Swiss boards and compensation committees

Professional Memberships

Swiss Bar Association

Zurich Bar Association

IBA International Bar Association

Market Perception

"Has very deep M&A experience, outstanding negotiator and very articulate in explaining complex issues." (IFLR 2025)

"Always available, unparalleled know-how in the Swiss market, good listener, quick to deliver, responsive to feedback." (IFLR 2025)

"Very hard-working and responsive (at all times, at short notice). Very knowledgeable and experienced. Pragmatic, actionable advice and solutions. Very concise and clear communication. Fair billing and no attempts to inflate efforts required on a given matter/project." (IFLR 2025)

"Andreas Müller is a standout expert in VegüV, corporate law, and other complex legal matters, known for his deep legal knowledge and personalised, strategic advice. What sets him apart is his ability to connect with clients on a personal level, offering clear communication and a genuine commitment to their success. His unique combination of legal acumen and people skills allows him to simplify complex issues, deliver tailored solutions, and build strong, lasting relationships. As both an exceptional lawyer and a trusted advisor, Andreas is recognised for his leadership, empathy, and dedication to achieving the best outcomes." (Legal 500 2025)

"Andreas Müller (M&A) provided highly professional, comprehensive and straightforward advice. He distinguished himself from competitors through an outstanding level of subject-matter expertise, an entrepreneurial mindset and direct accessibility at all times. His straightforward style contributed to a pleasant and highly efficient collaboration. We would highly recommend him at any time for challenging M&A consulting mandates in the context of dynamic start-up companies and beyond." (Legal 500 2024)